Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.

There are questions about vuso-vec’s supporting and confirmatory trials.

The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.

Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.

A surprising no to both multiple myeloma uses puts the ball in the FDA's court.

The group has canned its first-generation project, hoping that a follow-on will reach more patients.